RS67727B1 - Augmentirana kisela alfa-glukozidaza za lečenje pompeove bolesti - Google Patents

Augmentirana kisela alfa-glukozidaza za lečenje pompeove bolesti

Info

Publication number
RS67727B1
RS67727B1 RS20260146A RSP20260146A RS67727B1 RS 67727 B1 RS67727 B1 RS 67727B1 RS 20260146 A RS20260146 A RS 20260146A RS P20260146 A RSP20260146 A RS P20260146A RS 67727 B1 RS67727 B1 RS 67727B1
Authority
RS
Serbia
Prior art keywords
glucosidase
treatment
acid alpha
pompe disease
augmented
Prior art date
Application number
RS20260146A
Other languages
English (en)
Inventor
Hung V Do
Richie Khanna
Russell Gotschall
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of RS67727B1 publication Critical patent/RS67727B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
RS20260146A 2015-12-30 2016-12-29 Augmentirana kisela alfa-glukozidaza za lečenje pompeove bolesti RS67727B1 (sr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562272890P 2015-12-30 2015-12-30
US201662300479P 2016-02-26 2016-02-26
US201662315412P 2016-03-30 2016-03-30
US201662402454P 2016-09-30 2016-09-30
US201662428867P 2016-12-01 2016-12-01
US201662431791P 2016-12-08 2016-12-08
EP23188938.7A EP4285902B1 (en) 2015-12-30 2016-12-29 Augmented acid alpha-glucosidase for the treatment of pompe disease

Publications (1)

Publication Number Publication Date
RS67727B1 true RS67727B1 (sr) 2026-03-31

Family

ID=60186557

Family Applications (3)

Application Number Title Priority Date Filing Date
RS20231076A RS64843B1 (sr) 2015-12-30 2016-12-29 Augmentirana kisela alfa-glukozidaza za lečenje pompeove bolesti
RS20260146A RS67727B1 (sr) 2015-12-30 2016-12-29 Augmentirana kisela alfa-glukozidaza za lečenje pompeove bolesti
RS20210984A RS62212B1 (sr) 2015-12-30 2016-12-29 Augmentirana kiselina alfa-glukozidaza za lečenje pompeove bolesti

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RS20231076A RS64843B1 (sr) 2015-12-30 2016-12-29 Augmentirana kisela alfa-glukozidaza za lečenje pompeove bolesti

Family Applications After (1)

Application Number Title Priority Date Filing Date
RS20210984A RS62212B1 (sr) 2015-12-30 2016-12-29 Augmentirana kiselina alfa-glukozidaza za lečenje pompeove bolesti

Country Status (16)

Country Link
EP (4) EP4706779A2 (sr)
CN (1) CN108472340A (sr)
CY (1) CY1124637T1 (sr)
DK (3) DK3397273T3 (sr)
ES (3) ES2883844T3 (sr)
FI (2) FI4285902T3 (sr)
HK (1) HK1253014A1 (sr)
HR (3) HRP20231465T1 (sr)
HU (2) HUE054733T2 (sr)
LT (3) LT3397273T (sr)
PL (3) PL4285902T3 (sr)
PT (3) PT3397273T (sr)
RS (3) RS64843B1 (sr)
SI (3) SI4285902T1 (sr)
SM (3) SMT202100452T1 (sr)
TW (3) TW202506173A (sr)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723296B2 (en) * 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
PT2857036T (pt) 2003-01-31 2017-03-13 Mount Sinai School Of Medicine Of N Y Univ Terapia combinada para o tratamento de distúrbios de deficiência proteica
CA2553955C (en) * 2004-02-10 2012-08-28 Zystor Therapeutics, Inc. Acid alpha-glucosidase and fragments thereof
AU2006247065B8 (en) 2005-05-17 2012-07-12 Amicus Therapeutics, Inc. A method for the treatment of Pompe disease using 1-deoxynojirimycin derivatives
WO2009102895A2 (en) 2008-02-12 2009-08-20 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
WO2010138608A1 (en) * 2009-05-26 2010-12-02 Amicus Therapeutics, Inc. Utilization of pharmacological chaperones to improve manufacturing and purification of biologics
EP2844279B1 (en) 2012-05-03 2020-12-09 Amicus Therapeutics, Inc. Dosing regimens for the treatment of pompe disease
HK1209625A1 (en) 2012-07-17 2016-04-08 Amicus Therapeutics, Inc. Alpha-galactosidase a and 1-deoxygalactonojirimycin co-formulation
CN114540327B (zh) * 2014-09-30 2026-03-24 阿米库斯治疗学公司 具有增强的碳水化合物的高强度酸性α-葡糖苷酶

Also Published As

Publication number Publication date
EP3957320A1 (en) 2022-02-23
DK3957320T3 (da) 2023-11-27
EP3397273A1 (en) 2018-11-07
DK3397273T3 (da) 2021-08-09
TW202245831A (zh) 2022-12-01
EP3397273B1 (en) 2021-05-19
TWI849380B (zh) 2024-07-21
EP4706779A2 (en) 2026-03-11
TW202506173A (zh) 2025-02-16
TWI753874B (zh) 2022-02-01
SMT202600054T1 (it) 2026-03-09
PL4285902T3 (pl) 2026-04-13
LT3397273T (lt) 2021-06-25
HUE064049T2 (hu) 2024-02-28
FI4285902T3 (fi) 2026-02-17
SI3957320T1 (sl) 2024-01-31
FI3957320T3 (fi) 2023-11-23
HRP20260120T1 (hr) 2026-03-13
CY1124637T1 (el) 2022-07-22
HRP20231465T1 (hr) 2024-03-01
EP3957320B1 (en) 2023-08-23
PL3397273T3 (pl) 2021-12-06
DK3957320T5 (da) 2024-08-05
LT4285902T (lt) 2026-02-25
CN108472340A (zh) 2018-08-31
TW201726163A (zh) 2017-08-01
HK1253014A1 (zh) 2019-06-06
SMT202300412T1 (it) 2024-01-10
PT3957320T (pt) 2023-11-23
RS62212B1 (sr) 2021-09-30
DK4285902T3 (da) 2026-02-16
PT4285902T (pt) 2026-02-10
HRP20210894T1 (hr) 2021-07-23
SMT202100452T1 (it) 2021-09-14
RS64843B1 (sr) 2023-12-29
EP4285902B1 (en) 2025-11-19
HUE054733T2 (hu) 2021-09-28
ES3063549T3 (en) 2026-04-17
SI3397273T1 (sl) 2021-11-30
PL3957320T3 (pl) 2024-02-19
EP4285902A2 (en) 2023-12-06
EP4285902A3 (en) 2024-02-21
PT3397273T (pt) 2021-08-09
ES2965190T3 (es) 2024-04-11
ES2883844T3 (es) 2021-12-09
LT3957320T (lt) 2023-12-11
SI4285902T1 (sl) 2026-04-30

Similar Documents

Publication Publication Date Title
IL299470B2 (en) Improved acid alpha-glucosidase for the treatment of Pompe disease
IL259133A (en) Jamkaban combinations for the treatment of cardiovascular disease
LT3334422T (lt) Kanabidiolio rūgšties panaudojimas epilepsijos gydymui
IL253945A0 (en) kdm1a inhibitors to treat the disease
ZA201907552B (en) Recombinant human acid alpha-glucosidase
GB201500314D0 (en) Pharmaceutical formulations for the treatment of pulmonary arterial hypertension
IL255506A (en) A method for treating a neurological disease
EP3223809A4 (en) Amino acid compositions for the treatment of symptoms of disease
EP3310377A4 (en) Method of treating crohn's disease
IL253726B1 (en) Preparations for the treatment of inflammatory diseases related to uric acid
GB201515244D0 (en) Treatment of inflammatory disease or condition
SMT202300412T1 (it) Alfa-glucosidasi acida potenziata per il trattamento della malattia di pompe
GB201504413D0 (en) Treatment of disease
AU2015902286A0 (en) Method Of Treating Crohn's Disease
AU2015902358A0 (en) Treatment of inflammatory disease